Skip to Main Content

Good morning, everyone, and welcome to another working week. We hope the weekend respite was invigorating and relaxing, especially those of you on this side of the pond, where we had an extended break. Now, though, the usual routine of meetings, deadlines, and whatnot has, of course, returned. But what can you do? The world keeps spinning, after all. So please join us as we step into the Pharmalot cafeteria and brew another cup of stimulation to cope with the day ahead. Meanwhile, here are some tidbits to help you along. Hope you have a successful day.

Clinical trials being conducted in Wuhan, China, to test a Gilead Sciences (GILD) antiviral drug as a remedy for the coronavirus are going more slowly than hoped for as the drug maker struggles to recruit qualified patients, underscoring the challenges in quickly developing drugs during outbreaks, The Wall Street Journal reports. The trials, aimed at testing more than 700 patients infected with the coronavirus, have succeeded in recruiting fewer than 200 people after 10 days.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!